TrialRespiratory research2013

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.

Richard M A Follows et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.